Last checked at 10 Jul 2009 08:06
Friday 10 July 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Directors Holdings
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that, further to an announcement dated 6 July 2009, the 12,500,000 ordinary shares issued to Azure Ventures Limited, pursuant to a partial exercise of a warrant on 2 July 2009 have been admitted to trading on AIM.
Azure Ventures Limited is now interested in 116,666,666 shares, representing 42.19 per cent. of the Company's total voting rights.
Alejandro Weinstein, a non-executive director of the Company, is one of the ultimate beneficiaries under The Karjiang Pharma Trust which is the sole shareholder of Azure Ventures Limited.
The Company's issued share capital consists of 276,498,551 ordinary shares.
For further information
| Allergy Therapeutics | +44 (0) 1903 845 820 |
| Keith Carter, Chief Executive | |
| www.allergytherapeutics.com | |
| Nomura Code Securities | +44 (0) 207 776 1200 |
| Juliet Thompson/ Clare Terlouw | |
| Financial Dynamics | +44 (0) 207 831 3113 |
| Ben Brewerton/ Susan Quigley |